R-sulforaphane expression responses in three human breast-cell models
Cell-based study · ERα-positive MCF7 and ERα-negative MDA-MB-231 breast cancer cells; non-tumorigenic immortalized MCF10A breast epithelial cells. ERα expression was evaluated in MCF7 and MCF10A. [1]
A single comparative 72 h exposure design measured Nrf2, NQO1, GSTP, AhR and ERα expression. Figures report mean ± SEM from three independent experiments performed in triplicate, relative to control expression = 1. One-way ANOVA with Dunnett’s post hoc test assessed significance at p < 0.05. Gene-expression changes did not uniformly predict protein changes; functional estrogen metabolism, cancer prevention and treatment efficacy were not measured.
| Endpoint | Reported result | Reference |
|---|---|---|
| Nrf2 transcript and nuclear protein | Relative expression versus vehicle control Nuclear protein increased in all three cell lines; transcript responses depended on cell line and concentration. No exact fold values transcribed from bars. | [1] |
| NQO1 transcript and protein | Relative expression versus vehicle control Increased in MCF7, MDA-MB-231 and MCF10A; largest transcript/protein response reported in MCF7. | [1] |
| GSTP transcript and protein | Relative expression versus vehicle control Induction in breast cancer cells was concentration dependent; neither transcript nor protein was increased in MCF10A. | [1] |
| AhR transcript and protein | Relative expression versus vehicle control MCF7: decreased transcript and protein. MDA-MB-231: increased transcript without increased protein. MCF10A: protein unchanged. | [1] |
| ERα transcript and protein | Relative expression versus vehicle control At 20 µM, ERα transcript decreased in MCF7; ERα protein remained unchanged in MCF7 and MCF10A. | [1] |
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 µM in all cell lines; additionally 20 µM in MCF7 and MDA-MB-231, or 10 µM in MCF10A.
- Exposure duration
- 72 h exposure after a 24 h pre-incubation.
- Method
- Addition to cell culture; vehicle-treated cultures served as controls.
- Vehicle
- DMSO; vehicle controls not exceeding 0.1%.
- Reported limits
- R-SFN doses were selected using a cytotoxicity assay in a previous publication, which was not acquired; no viability or IC50 claim is adopted from that predecessor. Enantiomeric purity and product lot identity are not established here.
Methods and source locations
Compound reported in the paper: (R)-Sulforaphane; Compound label in the paper: R-SFN; (−)1-isothiocyanato-4R-(methylsulfinyl)-butane
Evidence concerns the authors’ reported R-SFN reagent in cultured human cells, with model-specific expression endpoints.
Materials and methods: Chemicals, Cell culture and treatment, Real-time PCR, Western blot analysis, Statistical analysis; Results; Figs. 1–4 and captions; Discussion
Nrf2 transcript and nuclear protein: RT-qPCR normalized to TBP/PBGD; immunoblotting with lamin control. — Results: The effect of R-sulforaphane on the expression of Nrf2; Fig. 2a–c; Methods: Real-time PCR and Western blot analysis
NQO1 transcript and protein: RT-qPCR and cytosolic immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of phase II enzymes; Fig. 1a–c
GSTP transcript and protein: RT-qPCR and cytosolic immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of phase II enzymes; Fig. 1d–f
AhR transcript and protein: RT-qPCR and whole-cell immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of AhR; Fig. 3a–c
ERα transcript and protein: RT-qPCR and whole-cell immunoblotting with β-actin control. — Results: The effect of R-sulforaphane on the expression of ERα; Fig. 4a–c